NCT02698306

Brief Summary

The investigators will select 30 patients with symmetrical impaction of third molars, according to Pell and Gregory dental impaction classification, who would be submitted to two surgical procedures, right and left, and in both surgeries dexamethasone 8 mg was administered in the pre-surgery phase, and the use of dexamethasone (12 mg/day) for 3 days on one side and diclofenac sodium (150 mg/day) for 3 days on the other side was continued, in a randomized, double-blind and cross-over trial so that all patients acted as control of themselves (split-mouth). Other drugs used in postoperative period, rescue analgesic and antibiotic therapy will be identical for all patients. The analyzed variables will be the visual analogue pain scale (VAS), total number of consumed analgesics, swelling and trismus (objectively), which were statistically analyzed by means of Student's t-test.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

February 9, 2016

Completed
21 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 3, 2016

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

March 3, 2016

Status Verified

February 1, 2016

Enrollment Period

1.1 years

First QC Date

February 9, 2016

Last Update Submit

February 28, 2016

Conditions

Outcome Measures

Primary Outcomes (3)

  • Pain assessed with a Visual Analog Scale

    1 week

  • Swelling measured by an scale in mm

    1 week

  • Mouth Opening measured by an scale in mm

    1 week

Study Arms (2)

Dexamethasone

EXPERIMENTAL

Dexamethasone: Dexametasone 4mg tablet every 8/8hs for 3 days

Drug: Dexamethasone

Diclofenac Sodium

ACTIVE COMPARATOR

Diclofenac Sodium: Diclofenac Sodium 50 mg tablet every 8/8 hs for 3 days

Drug: Diclofenac Sodium

Interventions

Dexamethasone

Also known as: Decadron
Dexamethasone

Diclofenac Sodium

Also known as: Voltarem
Diclofenac Sodium

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \- Patients had to have four third molars indicating the need for extraction and in any position of impact, as long as there was symmetry between the two sides.

You may not qualify if:

  • Patients with a history of alcoholism, drug use, antihistamine drugs, antidepressants, cimetidine or any drug that could interfere with the painful sensitivity of the patient.
  • Patients with systemic disorders such as diabetes, hypertension, heart disease, allergy to any component of the formula, sulfa drugs and also pregnant women, nursing mothers, persons experiencing dental fear and children were excluded.
  • Patients who had pericoronitis and/or radiolucent images associated with the teeth to be extracted

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Geral de Vila Penteado

São Paulo, São Paulo, 02802-120, Brazil

RECRUITING

MeSH Terms

Interventions

DexamethasoneCalcium DobesilateDiclofenac

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedBenzenesulfonatesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsArylsulfonatesArylsulfonic AcidsSulfonic AcidsSulfur AcidsSulfur CompoundsPhenylacetatesAcids, CarbocyclicCarboxylic Acids

Study Officials

  • Fábio Ricardo L. Sato, PhD

    Hospital Geral de Vila Penteado

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fábio Ricardo L Sato, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 9, 2016

First Posted

March 3, 2016

Study Start

February 1, 2015

Primary Completion

March 1, 2016

Study Completion

July 1, 2016

Last Updated

March 3, 2016

Record last verified: 2016-02

Data Sharing

IPD Sharing
Will not share

Locations